In the SURMOUNT program (SM), treatment with tirzepatide led to a significant and clinically meaningful reduction in body weight (BW) in overweight and obese subjects. In a post-hoc analysis, the effect of tirzepatide treatment on body weight in women was examined according to the stage of menopause.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Blastic plasmacytoid dendritic cell neoplasia
Rare malignancy from a dermatological perspective
- Psychooncology
Communication as the key to therapy adherence
- From symptom to diagnosis
Lung carcinoma – Pancoast tumor
- Deep vein thrombosis
Outpatient or inpatient treatment?
- From symptom to diagnosis
Abdominal pain – Intraductal papillary mucinous neoplasia
- IBDmatters - Advanced Therapeutic Treatments
Examinations and considerations before therapy
- “Swiss Health Care Atlas”
Supply situation in Switzerland at a glance
- Steatotic liver disease